BackSpero Therapeutics Overview

Spero Therapeutics Net Income

Latest net income for SPRO: $-30M, below the Healthcare sector average of $1.5T.

Get informed when a big investor buys or sells

+ Follow

Quarterly Net Income

-$44.28M
↓ 499.81% YoY

As of Sep 2026

Annual Net Income (TTM)

-$29.51M
↑ 1.52% YoY

Trailing 12 months ending Sep 2026

Average Net Income (Comparison Companies)

Loading

Net Income History

Loading

Net Income Comparison

Loading

Annual Net Income Growth Rate (%)

Loading...

Annual Net Income Growth (Absolute)

Loading...

Spero Therapeutics (SPRO) FAQ

The latest net income for SPRO is $-30M as of September 2026. That compares with $-30M in the prior-year period — up 1.5% year over year. That is below the Healthcare sector average of $1.5T. Investors often review this figure alongside Spero Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, SPRO's net income moved from $-30M to $-30M — a 1.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Spero Therapeutics's operating scale or balance-sheet position.

Against Healthcare companies, SPRO currently prints $-30M for net income, while the sector average sits near $1.5T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Spero Therapeutics's growth, margins, and balance sheet.

A net income figure of $-30M for SPRO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $1.5T. Explore the charts below for those layers of context.

After noting SPRO's net income ($-30M), review year-over-year change from $-30M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.